Literature DB >> 9426450

Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis.

D L Jones1, D A Thompson, K Münger.   

Abstract

Cells that express the human papillomavirus (HPV) type 16 E7 oncoprotein are predisposed to undergo apoptosis. Transgenic mice that have E7 expression targeted to either the retinal photoreceptor cells or the lens cells exhibit signs of apoptosis in cells attempting to undergo differentiation. We established a cell culture system to study this process and have determined the domains of E7 that are required for predisposing cells to undergo apoptosis in response to growth arrest signals. Regions within the core pRB binding site of E7 were necessary but not sufficient for inducing apoptosis. Residues within the adenovirus conserved region 1 homology domain and the consensus casein kinase II phosphorylation site are also important for this effect on cell viability. Our data also demonstrate that the ability of E7 to induce destabilization of pRB and stabilization of p53 coincides with E7-mediated transformation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426450     DOI: 10.1006/viro.1997.8851

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  101 in total

1.  Clink, a nanovirus-encoded protein, binds both pRB and SKP1.

Authors:  M N Aronson; A D Meyer; J Györgyey; L Katul; H J Vetten; B Gronenborn; T Timchenko
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.

Authors:  A M Helt; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.

Authors:  S L Gonzalez; M Stremlau; X He; J R Basile; K Münger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.

Authors:  S Nakagawa; J M Huibregtse
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 5.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 6.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

7.  Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization.

Authors:  Erik R Vandermark; Krysta A Deluca; Courtney R Gardner; Daniel F Marker; Cynthia N Schreiner; David A Strickland; Katelynn M Wilton; Sumona Mondal; Craig D Woodworth
Journal:  Virology       Date:  2012-01-28       Impact factor: 3.616

8.  Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.

Authors:  Anna-Marija Helt; Jens Oliver Funk; Denise A Galloway
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7.

Authors:  Wanxia He; Doug Staples; Clark Smith; Chris Fisher
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600.

Authors:  Kyung-Won Huh; Joseph DeMasi; Hidesato Ogawa; Yoshihiro Nakatani; Peter M Howley; Karl Münger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.